Document is current
Any future updates will be listed below
-
Authors
Karl, Anna-Sophia
Klimas, Rafael https://orcid.org/0000-0001-5989-2195
Katsimpoura, Melina
Sgodzai, Melissa
Theile-Ochel, Simon
Poser, Philip Lennart
Gisevius, Barbara
Faissner, Simon
Salmen, Anke
Nastos, Ilias
Gold, Ralf
Motte, Jeremias
-
Funding
Funding for this research was provided by:
Katholisches Klinikum Bochum gGmbh
- License Information
-
More Information
Article History
Received: 27 May 2024
Revised: 10 July 2024
Accepted: 12 July 2024
First Online: 22 July 2024
Declarations
:
: Anna-Sophia Karl: none. Rafael Klimas: received travel support from Takeda, Grifols, Ruhr-University Bochum and research support by Ruhr-University Bochum, and LFB Group France; none related to this manuscript. Melina Katsimpoura: none. Philip Lennart Poser: none. Simon Theile-Ochel: none. Melissa Sgodzai: none. Barbara Gisevius: none. Simon Faissner: has received speaker’s and/or scientific board honoraria and/or congress travel support from Academy2, AstraZeneca, Biogen, BMS, Celgene, Genesis Pharma, Hexal, Janssen, Merck, Neuraxpharm, Novartis and Roche and grant support from Ruhr-University Bochum, German Research Foundation (DFG), DMSG, DMSG North-Rhine-Westfalia, Stiftung für therapeutische Forschung, Lead Discovery Center GmbH and Novartis; none related to this manuscript. Anke Salmen: received speaker honoraria for activities with Bristol Myers Squibb, CSL Behring, Novartis, and Roche, and research support by the Baasch Medicus Foundation, the Medical Faculty of the University of Bern, the Swiss MS Society and the regional association of North Rhine-Westphalia of the German MS Society (DMSG Landesverband NRW). Ralf Gold: serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis; has received speaker honoraria from Biogen Idec, Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, and Novartis; serves as editor for Therapeutic Advances in Neurological Diseases and on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis, none related to this manuscript. Jeremias Motte: received speaker honoraria for activities with Alnylam, Biogen Idec, travel grants from Biogen Idec, Novartis AG, Teva, and Eisai GmbH; and his research is supported by Biogen Idec, Novartis AG, Kyverna Therapeutics Inc., GBS/CIDP Foundation International, Klaus TschiraFoundation, Hertie Foundation and Ruhr-University, Bochum, regional association of North Rhine-Westphalia of the German MS Society (DMSG Landesverband NRW); none related to this manuscript.
: The study was conducted in accordance with the Declaration of Helsinki of 1975 and approved by the local ethics committee of the Ruhr University Bochum (20-6827).
